Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

ABSTRACT: PURPOSE: Clinical Treatment Score at 5 years (CTS5) is a prognostic tool to estimate distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women with oestrogen receptor-positive (ER-positive) breast cancer. METHODS: The validity of CTS5 was tested in a retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Richman, Juliet, Ring, Alistair, Dowsett, Mitch, Sestak, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940308/
https://www.ncbi.nlm.nih.gov/pubmed/33222093
http://dx.doi.org/10.1007/s10549-020-06013-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940308/
https://www.ncbi.nlm.nih.gov/pubmed/33222093
http://dx.doi.org/10.1007/s10549-020-06013-6

Ejemplares similares